Non-Small Cell Lung Cancer (NSCLC) | Norton Healthcare

Indication: Non-Small Cell Lung Cancer (NSCLC)

LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields)in combination with PD-1 inhibitors or docetaxel, for second line treatment of non-small cell lung cancer (NSCLC)

Second Line Metastatic

Sub-indication: PD-1 inhibitor or docetaxel +/- TTFields in NSCLC following platinum base therapy

Line of Therapy: 2nd line treatment NSCLC following platinum based therapy

Device - IDE

Principal Investigator: Adam Lye, M.D.
Norton Cancer Institute

Sponsor: NovoCure

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.